Washington, D.C. (August 3, 2017) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:
“PhRMA applauds the Senate for passage of the Prescription Drug, Biosimilar and Generic Drug User Fee Acts. PDUFA VI better incorporates real-world evidence and patient perspectives into the drug development and approval process, while also providing the U.S. Food and Drug Administration (FDA) with new tools and resources to keep up with the latest scientific advances. By strengthening the FDA and improving efficiency in the drug review process, we can bring safe, innovative medicines to patients faster, which will enhance competition and lower costs. This is a major victory for medical innovation, the FDA and patients.
“We commend the bipartisan efforts of legislators from both the Senate and House including Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, Ranking Member Patty Murray, along with House Energy and Commerce Committee Chairman Greg Walden and Ranking Member Frank Pallone for advancing this critical legislation.
“We further look forward to working with the FDA to implement PDUFA VI.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: